Bausch & Lomb today announced it has acquired the commercial assets ofTubilux Pharma S.p.A. Tubilux is a privately held ophthalmic pharmaceuticals company thatdevelops and markets a range of proprietary, over-the-counter, and brandedgeneric products primarily in Italy, and with distribution in approximately 30other countries. Under the terms of the agreement, Bausch & Lomb has acquired the company’sophthalmic pharmaceuticals portfolio, as well as its commercial and salesoperations. Group Tubilux will retain its manufacturing operation, producingexisting products for Bausch & Lomb under a multi-year contract.”This agreement more than doubles our presence in the Italian ophthalmicpharmaceuticals market,” said Charl van Zyl, head of Bausch & Lomb’sPharmaceuticals business for Europe, Middle East and Africa. “Bausch & Lomb iscommitted to expanding our portfolio offerings, and we believe that thisinvestment will prove successful for the company, doctors and patients alike.”The acquired Tubilux portfolio includes products for dry eye relief(Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); foranti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).”As a result of this transaction, Tubilux will strengthen its focus andpresence in the ophthalmic pharmaceutical contract manufacturing sector,including ointments, gels and eye drop formats,” said Emidio Fedeli, chiefexecutive officer of Group Tubilux.
